Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZRX AzurRx BioPharma	$0.39 -2.4%	$4.04	$3.36 ▼ $26.30	$3.64M	1.51	628,703 shs	79,431 shs
KZIA Novogen	$6.58 -0.8%	$5.15	$2.86 ▼ $79.00	$6.68M	2.64	384,609 shs	11,729 shs
SEEL Seelos Therapeutics		$0.00	$0.37 ▼ $698.88	N/A	1.94	174,745 shs	2 shs
SXTC China SXT Pharmaceuticals	$1.78 -7.3%	$1.79	$0.95 ▼ $11.92	$30.39M	1.18	1.19 million shs	31,284 shs
UMRX Cogent Biosciences	$7.22 +0.6%	$10.50	$0.29 ▼ $3.72	$306.63M	3.93	1.22 million shs	2.32 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZRX AzurRx BioPharma	+5.54%	-20.06%	-7.73%	-2.46%	-64.29%
KZIA Novogen	+5.74%	+8.51%	+75.40%	+65.75%	-38.84%
SEEL Seelos Therapeutics	0.00%	0.00%	0.00%	0.00%	-99.99%
SXTC China SXT Pharmaceuticals	+10.98%	+6.08%	+39.14%	-25.29%	-77.14%
UMRX Cogent Biosciences	+1.13%	-1.10%	+31.99%	+24.01%	-19.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KZIA Novogen	3.2262 of 5 stars	3.5	2.0	0.0	0.0	3.8	0.0	0.0
SEEL Seelos Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	0.3514 of 5 stars	0.0	3.0	0.0	0.0	1.6	0.0	0.6
UMRX Cogent Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZRX AzurRx BioPharma	0.00	N/A	N/A	N/A
KZIA Novogen	3.00	Buy	$57.50	773.86% Upside
SEEL Seelos Therapeutics	0.00	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A
UMRX Cogent Biosciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AZRX, UMRX, KZIA, SEEL, and SXTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/11/2025	KZIA Novogen	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00

(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	($0.76) per share	N/A
KZIA Novogen	$1.51M	4.40	N/A	N/A	($9.87) per share	-0.67
SEEL Seelos Therapeutics	$2.20M	0.00	N/A	N/A	($437.92) per share	0.00
SXTC China SXT Pharmaceuticals	$1.93M	14.60	N/A	N/A	$243.66 per share	0.01
UMRX Cogent Biosciences	$22.50M	13.63	N/A	N/A	$1.04 per share	6.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZRX AzurRx BioPharma	-$32.67M	-$11.50	N/A	N/A	N/A	N/A	-482.96%	-258.47%	N/A
KZIA Novogen	-$17.56M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
SEEL Seelos Therapeutics	-$37.88M	N/A	0.00	N/A	N/A	203.13%	N/A	-431.47%	N/A
SXTC China SXT Pharmaceuticals	-$3.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
UMRX Cogent Biosciences	-$31.83M	-$1.04	N/A	N/A	N/A	-96.84%	-87.78%	-52.14%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	N/A
KZIA Novogen	N/A	N/A	N/A	N/A	N/A
SEEL Seelos Therapeutics	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UMRX Cogent Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZRX AzurRx BioPharma	N/A	1.33	1.33
KZIA Novogen	N/A	0.21	N/A
SEEL Seelos Therapeutics	N/A	0.08	0.08
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A
UMRX Cogent Biosciences	0.18	2.90	2.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZRX AzurRx BioPharma	6.27%
KZIA Novogen	30.89%
SEEL Seelos Therapeutics	23.37%
SXTC China SXT Pharmaceuticals	5.02%
UMRX Cogent Biosciences	26.39%

Insider Ownership

Company	Insider Ownership
AZRX AzurRx BioPharma	7.30%
KZIA Novogen	1.00%
SEEL Seelos Therapeutics	1.08%
SXTC China SXT Pharmaceuticals	3.95%
UMRX Cogent Biosciences	31.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZRX AzurRx BioPharma	12	9.33 million	8.65 million	Not Optionable
KZIA Novogen	12	1.01 million	997,000	Optionable
SEEL Seelos Therapeutics	20	372,000	368,000	Optionable
SXTC China SXT Pharmaceuticals	90	15.83 million	15.20 million	Not Optionable
UMRX Cogent Biosciences	72	42.47 million	N/A	Not Optionable

AZRX, UMRX, KZIA, SEEL, and SXTC Headlines

Recent News About These Companies

Cogent Biosciences Secures $400 Million Debt Financing Facility to Support Growth and Upcoming Bezuclastinib Launch

June 11, 2025 | quiverquant.comQ

Why Cogent Biosciences (COGT) Is One of the Best Low Priced Biotech Stocks to Buy Now

May 13, 2025 | insidermonkey.com

Cogent Biosciences Advances with Promising Clinical Trials

May 6, 2025 | tipranks.com

Is Cogent Biosciences, Inc. (COGT) the Best Small Cap Stock to Buy with the Biggest Upside Potential?

May 5, 2025 | insidermonkey.com

Cogent Biosciences (COGT): Among the Most Promising Penny Stocks According to Analysts

April 20, 2025 | insidermonkey.com

Is Cogent Biosciences Inc. (NASDAQ:COGT) the Best Biotech Penny Stock to Buy According to Hedge Funds?

April 17, 2025 | msn.com

Cogent Biosciences (COGT): Among the Best Biotech Stocks to Buy According to Billionaires

March 18, 2025 | msn.com

Is Cogent Biosciences, Inc. (COGT) a Best Biotech Stock According to Billionaires?

March 17, 2025 | insidermonkey.com

Cogent Biosciences (COGT) Initiated with a Buy at Scotiabank

March 10, 2025 | markets.businessinsider.com

Cogent Biosciences initiated with an Outperform at Scotiabank

March 7, 2025 | markets.businessinsider.com

Cogent Biosciences reports Q4 net loss $67.9M vs. $54.4M last year

February 25, 2025 | markets.businessinsider.com

Cogent Biosciences sees cash runway into late 2026

February 25, 2025 | markets.businessinsider.com

Cogent Biosciences Inc (COGT) Stock: More Resilient Than It Appears

January 24, 2025 | bovnews.comB

Cogent Biosciences exec buys $332K in common stock

January 16, 2025 | markets.businessinsider.com

Piper Sandler Sticks to Its Buy Rating for Cogent Biosciences (COGT)

January 14, 2025 | markets.businessinsider.com

Cogent Biosciences price target lowered to $14 from $17 at H.C. Wainwright

January 14, 2025 | markets.businessinsider.com

Cogent Biosciences (COGT) Gets a Buy from J.P. Morgan

December 19, 2024 | markets.businessinsider.com

Cogent Biosciences Reports Promising APEX Phase 2 Trial Results for Bezuclastinib in Advanced Systemic Mastocytosis at ASH 2024

December 8, 2024 | quiverquant.comQ

Cogent Biosciences price target raised to $21 from $19 at JPMorgan

November 15, 2024 | markets.businessinsider.com

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results

November 12, 2024 | tmcnet.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AZRX, UMRX, KZIA, SEEL, and SXTC Company Descriptions

AzurRx BioPharma NASDAQ:AZRX

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.

Novogen NASDAQ:KZIA

$6.58 -0.05 (-0.75%)

Closing price 03:59 PM Eastern

Extended Trading

$6.39 -0.19 (-2.89%)

As of 06:35 PM Eastern

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Seelos Therapeutics NASDAQ:SEEL

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.78 -0.14 (-7.29%)

Closing price 04:00 PM Eastern

Extended Trading

$1.81 +0.03 (+1.69%)

As of 07:54 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Cogent Biosciences NASDAQ:UMRX

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time